未登录

A

Aatke van der Maas

sint maartens clinic

H指数:20

被引数:1,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial

皮下与静脉超低剂量利妥昔单抗在类风湿关节炎中的比较：一项随机对照药代动力学-药效学非劣效性试验

IF4.4

2026-08-180

OAAI

Glucocorticoid tapering strategies in polymyalgia rheumatica: a systematic literature review

类风湿多肌炎中糖皮质激素减量策略：一项系统文献综述

IF4.4

2026-02-010

PRE

Measurement properties of the Polymyalgia Rheumatica Activity Score (PMR-AS): reliability, measurement error and discriminative validity

强直性肌炎活动评分（PMR-AS）的测量属性：信度、测量误差和区分效度

IF4.4

2026-02-011

PRE

Non-Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-07-270

OAAI

1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double- blind placebo-controlled trial

LANCET RHEUMATOLOGY

IF16.4

2023-04-0110

PRE

Measurement Properties of the Polymyalgia Rheumatica Activity Score: A Systematic Literature Review

JOURNAL OF RHEUMATOLOGY

IF3.4

2022-03-015

PRE

Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial

LANCET RHEUMATOLOGY

IF16.4

2021-11-0133

PREAI

Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study

RHEUMATOLOGY INTERNATIONAL

IF2.9

2021-01-237

PREAI

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

COCHRANE DATABASE OF SYSTEMATIC REVIEWS

IF9.4

2019-05-2461

OA

Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2017-04-2421

PREAI

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2016-11-0141

PREAI

STUDY ON ABATACEPT AND TOCILIZUMAB ATTENUATION (SONATA) IN RHEUMATOID ARTHRITIS PATIENTS: A RETROSPECTIVE, EXPLORATIVE COHORT STUDY

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2016-06-011

PREAI

RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS TAPERING TNF INHIBITORS IS PRIMARILY DRIVEN BY MEAN DISEASE ACTIVITY OVER TIME, NOT SO MUCH BY FLARING OR LOWER TNF INHIBITOR EXPOSITION

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2016-06-011

PREAI

Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2015-12-0114

PREAI

CONTROLLING THE COST SPENT ON EXPENSIVE BIOLOGIC AGENTS: AN EXAMPLE OF NET MONETARY SAVINGS BY DOSE OPTIMISATION OF TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS

VALUE IN HEALTH

IF6

2015-11-010

OAAI

PREDICTIVE VALUE OF A MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR SUCCESSFUL DOSE REDUCTION OF TNF INHIBITORS IN RHEUMATOID ARTHRITIS: RESULTS OF THE DRESS STUDY

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2015-06-011

PREAI

ASSOCIATIONS OF A MULTI-BIOMARKER DISEASE ACTIVITY SCORE WITH CLINICAL AND RADIOGRAPHIC PARAMETERS IN RHEUMATOID ARTHRITIS

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2015-06-011

PREAI

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2015-04-09120

OAAI

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

COCHRANE DATABASE OF SYSTEMATIC REVIEWS

IF9.4

2014-09-2972

PREAI

VALIDITY OF OMERACT PRELIMINARY FLARE QUESTIONS IN A RANDOMIZED CONTROLLED TRIAL, THAT ASSESSES IMPACT OF DISEASE ACTIVITY GUIDED DOWN-TITRATION OF ANTI-TNF TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS IN LOW DISEASE ACTIVITY

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2014-06-011

PREAI